Remote electrocardiogram monitoring in cancer patients for detecting cardiotoxicity. Case report

Cover Page

Cite item

Full Text

Abstract

Cardiotoxicity is the direct adverse effect of anticancer agents on the function or structure of the heart, occurring both during treatment and many years later. The manifestations of cardiotoxicity can be very different: heart failure, coronary heart disease, cardiomyopathy, myocarditis, pericarditis, and arrhythmias, including atrial fibrillation (AF). The incidence of AF in the cancer patient population during therapy is 20–30%. Current options of remote electrocardiogram monitoring ensure the timely detection and treatment of AF in cancer patients, including the administration of anticoagulants. The article presents a clinical case of a 59-year-old patient with squamous cell carcinoma of the lower third of the esophagus after the first course of the TPF polychemotherapy regimen (docetaxel, cisplatin, 5-fluorouracil) with AF detected using a single-channel electrocardiogram monitor in a smartphone case.

About the authors

Dinara F. Mesitskaya

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: aranid980@gmail.com
ORCID iD: 0000-0003-3541-6041

канд. мед. наук, доц. каф. кардиологии, функциональной и ультразвуковой диагностики Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Anastasia S. Yasneva

Sechenov First Moscow State Medical University (Sechenov University)

Email: aranid980@gmail.com
ORCID iD: 0000-0003-3009-4143

студентка Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Zaki Z. Fashafsha

Sechenov First Moscow State Medical University (Sechenov University)

Email: aranid980@gmail.com
ORCID iD: 0000-0001-5473-3101

науч. сотр. Института персонализированной кардиологии научно-исследовательского центра мирового уровня «Цифровой биодизайн и персонализированное здравоохранение»

Russian Federation, Moscow

Philipp Yu. Kopylov

Sechenov First Moscow State Medical University (Sechenov University)

Email: aranid980@gmail.com
ORCID iD: 0000-0002-4535-8685

д-р мед. наук, проф., дир. Института персонализированной кардиологии научно-исследовательского центра мирового уровня «Цифровой биодизайн и персонализированное здравоохранение»

Russian Federation, Moscow

Denis A. Andreev

Sechenov First Moscow State Medical University (Sechenov University)

Email: aranid980@gmail.com
ORCID iD: 0000-0002-0276-7374

д-р мед. наук, проф., зав. каф. кардиологии, функциональной и ультразвуковой диагностики Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

References

  1. Xiao D, Li J, Liu Y, et al. Emerging trends and hotspots evolution in cardiotoxicity: A bibliometric and knowledge-Map analysis From 2010 to 2022. Front Cardiovasc Med. 2023;10:1089916. doi: 10.3389/fcvm.2023.1089916
  2. Hajjar LA, Fonseca SMR, Machado TIV. Atrial fibrillation and cancer. Front Cardiovasc Med. 2021;8:590768. doi: 10.3389/fcvm.2021.590768
  3. Jakobsen CB, Lamberts M, Carlson N, et al. Incidence of atrial fibrillation in different major cancer subtypes: A Nationwide population-based 12 year follow up study. BMC Cancer. 2019;19(1):1105. doi: 10.1186/s12885-019-6314-9
  4. Lancellotti P, Marechal P, Donis N, Oury C. Inflammation, cardiovascular disease, and cancer: A common link with far-reaching implications. Eur Heart J. 2019;40(48):3910-2. doi: 10.1093/eurheartj/ehz645
  5. Alexandre J, Salem JE, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312-20. doi: 10.1093/ehjcvp/pvaa037
  6. Herrmann J. Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474-502. doi: 10.1038/s41569-020-0348-1
  7. Ahmad J, Thurlapati A, Thotamgari S, et al. Anti-cancer drugs associated atrial fibrillation-an analysis of real-world pharmacovigilance data. Front Cardiovasc Med. 2022;9:739044. doi: 10.3389/fcvm.2022.739044
  8. Riess H, Ay C, Bauersachs R, et al. Use of direct oral anticoagulants in patients with cancer: Practical considerations for the management of patients with nausea or vomiting. Oncologist. 2018;23(7):822-39. doi: 10.1634/theoncologist.2017-0473
  9. Grymonprez M, De Backer TL, Bertels X, et al. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Front Pharmacol. 2023;14:1125576. doi: 10.3389/fphar.2023.1125576
  10. Ording AG, Horváth-Puhó E, Adelborg K, et al. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: A Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165-72. doi: 10.1002/cam4.1054
  11. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol. 2019;94(7):780-5. doi: 10.1002/ajh.25494
  12. Wu VC, Wang CL, Huang YT, et al. Novel oral anticoagulant versus warfarin in cancerpatients with atrial fibrillation: An 8-year population-based cohort study. J Cancer. 2020;11:92-9. doi: 10.7150/jca.36468
  13. Deng Y, Tong Y, Deng Y, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: A systematic review and meta-analysis. J Am Heart Assoc. 2019;8(14):e012540. doi: 10.1161/JAHA.119.012540
  14. Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: A study-level metaanalysis. Thromb Haemost. 2020;120(2):314-21. doi: 10.1055/s-0039-3400300
  15. Sawant AC, Kumar A, McCray W, et al. Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: A national veterans affairs database study. J Geriatr Cardiol. 2019;16(9):706-9. DOI:10.11909%2Fj.issn.1671-5411.2019.09.006
  16. Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2(3):200-9. doi: 10.1182/bloodadvances.2017010694
  17. Melloni C, Dunning A, Granger CB, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: Insights from the ARISTOTLE Trial. Am J Med. 2017;130(12):1440-48.e1. doi: 10.1016/j.amjmed.2017.06.026
  18. Haverkamp HT, Fosse SO, Schuster P. Accuracy and usability of single-lead ECG from smartphones – A clinical study. Indian Pacing Electrophysiol J. 2019;19(4):145-9. doi: 10.1016/j.ipej.2019.02.006
  19. Manetas-Stavrakakis N, Sotiropoulou IM, Paraskevas T, et al. Accuracy of artificial intelligence-based technologies for the diagnosis of atrial fibrillation: A systematic review and meta-analysis. J Clin Med. 2023;12(20):6576. doi: 10.3390/jcm12206576
  20. Badheeb AM, Ahmed F, Alzahrani HA, et al. Cancer therapy-related cardiotoxicity: A comprehensive retrospective analysis at Najran Cancer Center, Saudi Arabia. Cureus. 2023;15(7):e41287. doi: 10.7759/cureus.41287
  21. Costa IBSDS, Bittar CS, Fonseca SMR, et al. Brazilian cardio-oncology: The 10-year experience of the Instituto do Cancer do Estado de Sao Paulo. BMC Cardiovasc Disord. 2020;20(1):206. doi: 10.1186/s12872-020-01471-8
  22. Brandão SR, Carvalho F, Amado F, et al. Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. Metabolism. 2022;134:155250. doi: 10.1016/j.metabol.2022.155250
  23. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract (1995). 2019;47(1):6-15. doi: 10.1080/21548331.2018.1530831
  24. Alexandre J, Boismoreau L, Morice PM, et al. Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials. JACC CardioOncol. 2023;5(2):216-26. doi: 10.1016/j.jaccao.2022.11.019
  25. Adhikari A, Asdaq SMB, Al Hawaj MA, et al. Anticancer drug-induced cardiotoxicity: Insights and pharmacogenetics. Pharmaceuticals (Basel). 2021;14(10):970. doi: 10.3390/ph14100970
  26. Lobenwein D, Kocher F, Dobner S, et al. Cardiotoxic mechanisms of cancer immunotherapy – A systematic review. Int J Cardiol. 2021;323:179-87. doi: 10.1016/j.ijcard.2020.08.033
  27. Moriyama S, Yokoyama T, Irie K, et al. Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. J Cardiol Cases. 2019;20(5):183-6. doi: 10.1016/j.jccase.2019.08.005
  28. Peng H, Chen B, He S, et al. Efficacy and toxicity of three induction chemotherapy regimens in locoregionally advanced nasopharyngeal carcinoma: Outcomes of 10-year follow-up. Front Oncol. 2021;11:765378. doi: 10.3389/fonc.2021.765378
  29. Diederichsen SZ, Haugan KJ, Brandes A, et al. Natural history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll Cardiol. 2019;74(22):2771-81. doi: 10.1016/j.jacc.2019.09.050
  30. Gognieva D, Vishnyakova N, Mitina Y, et al. Remote screening for atrial fibrillation by a federal cardiac monitoring system in primary care patients in Russia: Results from the Prospective Interventional Multicenter FECAS-AFS Study. Glob Heart. 2022;17(1):4. doi: 10.5334/gh.1057

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Remote single-channel ECG monitoring using the CardioQVARK device before the first course of polychemotherapy. Sinus rhythm with a heart rate of 75 beats per minute.

Download (46KB)
Indexing metadata
3. Fig. 2. Single-channel ECG using the CardioQVARK device before the second course of polychemotherapy. Normosystolic form of atrial fibrillation.

Download (51KB)
Indexing metadata

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies